Investigating a new approach to reduce lung fibrosis
Official title: Fibronectin Extra Domain A Degradation as an Antifibrotic Approach in Lung Fibrosis
Funded at University of Pittsburgh at Pittsburgh · NIH-11056059 · Data updated 2026-11-12
This study is looking at a protein called FN-EDA to see how it affects lung fibrosis, a condition that makes it hard to breathe, and aims to find new ways to help people with this condition feel better.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $118,070 |
| NIH project number | 5R03HL173071-02 |
| Project ID | NIH-11056059 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis or related interstitial lung diseases.
✕Less likely to help
Patients with acute lung injuries or those without any form of lung fibrosis may not benefit from this research.
What this research studies
This research focuses on understanding how a specific protein variant, Fibronectin Extra Domain A (FN-EDA), contributes to lung fibrosis, a serious condition that thickens lung tissue and impairs breathing. The study aims to explore the mechanisms of protein degradation that could potentially reduce fibrosis. By targeting FN-EDA, the researchers hope to develop new therapeutic strategies to alleviate the symptoms and progression of chronic lung diseases. Patients with pulmonary fibrosis may benefit from insights gained through this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life and survival rates for patients with lung fibrosis.
How similar studies have gone: Previous research has shown promise in targeting similar pathways for treating fibrotic diseases, indicating that this approach could be a viable option.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Evankovich, John W — University of Pittsburgh at Pittsburgh
- Study coordinator: Evankovich, John W
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.